NASDAQ:CELU

Celularity Stock Insider Trading

Healthcare > Biotechnology

Buy CELU

*Your capital is at risk

$0.755

+0.0147 (+1.99%)

At Close: Jul 13, 2026

Celularity Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 41.76. In total, the insiders bought 20.26M and sold 10.06M CELU shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	41.76
● Buy	20.26M shares
● Sell	10.06M shares
72% Buy Activity Moderate Positive Correlation
Sell Signal Low Confidence Jun 22, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 41.76. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 19, 2026 Sell	Convertible Notes J-Other	Barach Daniele Wolf 10 Percent Owner	10% Owner	1 204 819 Value: $2.00M
Jun 19, 2026 Sell	Convertible Notes J-Other	Philip & Daniele Barach Family Trust 10 Percent Owner	10% Owner	1 204 819 Value: $2.00M
Jun 19, 2026 Sell	Warrants J-Other	Philip & Daniele Barach Family Trust 10 Percent Owner	10% Owner	839 160 Value: $1.68M
Jun 19, 2026 Sell	Convertible Notes J-Other	Barach Philip Alan 10 Percent Owner	10% Owner	1 204 819 Value: $2.00M
Jun 19, 2026 Sell	Warrants J-Other	Barach Philip Alan 10 Percent Owner	10% Owner	839 160 Value: $1.68M
Jun 19, 2026 Sell	Warrants J-Other	Barach Daniele Wolf 10 Percent Owner	10% Owner	839 160 Value: $1.68M
Jun 19, 2026 Buy	Warrants	Barach Philip Alan 10 Percent Owner	10% Owner	839 160 Value: $1.68M
Jun 19, 2026 Buy	Warrants	Barach Daniele Wolf 10 Percent Owner	10% Owner	839 160 Value: $1.68M
Jun 19, 2026 Buy	Warrants	Philip & Daniele Barach Family Trust 10 Percent Owner	10% Owner	839 160 Value: $1.68M
Apr 13, 2026 Buy	Restricted Stock Units M-Exempt	Hariri Robert J Chief Executive Officer	CEO / President	3 281 Value: $4K
Apr 13, 2026 Sell	Class A Common Stock F-InKind	Hariri Robert J Chief Executive Officer	CEO / President	1 182 Value: $2K
Apr 13, 2026 Buy	Class A Common Stock M-Exempt	Hariri Robert J Chief Executive Officer	CEO / President	3 281 Value: $4K
Apr 13, 2026 Buy	Class A Common Stock M-Exempt	Brigido Stephen Pres., Functional Regeneration	Officer	821 Value: $1K
Apr 13, 2026 Sell	Class A Common Stock F-InKind	Brigido Stephen Pres., Functional Regeneration	Officer	268 Value: $343
Apr 13, 2026 Buy	Restricted Stock Units M-Exempt	Brigido Stephen Pres., Functional Regeneration	Officer	821 Value: $1K
Apr 13, 2026 Buy	Class A Common Stock M-Exempt	Haines John R Senior Exec Vice President	CEO / President	1 641 Value: $2K
Apr 13, 2026 Sell	Class A Common Stock F-InKind	Haines John R Senior Exec Vice President	CEO / President	583 Value: $746
Apr 13, 2026 Buy	Restricted Stock Units M-Exempt	Haines John R Senior Exec Vice President	CEO / President	1 641 Value: $2K
Jan 12, 2026 Buy	Class A Common Stock A-Award	Parks Diane L. Director	Director	30 000 Value: $39.6K
Jan 12, 2026 Buy	Class A Common Stock A-Award	Diamandis Peter Director	Director	20 385 Value: $26.9K
Jan 12, 2026 Buy	Class A Common Stock A-Award	Ling Geoffrey M.d. Director	Director	19 231 Value: $25.4K
Jan 12, 2026 Buy	Class A Common Stock A-Award	Levien Vincent Director	Director	28 847 Value: $38.1K
Dec 29, 2025 Buy	Class A Common Stock A-Award	Diamandis Peter Director	Director	125 000 Value: $150.0K
Dec 29, 2025 Buy	Stock Options A-Award	Diamandis Peter Director	Director	156 250 Value: $187.5K
Dec 29, 2025 Buy	Class A Common Stock A-Award	Parks Diane L. Director	Director	125 000 Value: $150.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT CELULARITY INC.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-...

Read Full Profile Here